Prescription medication · GLP-1 Receptor Agonist
dulaglutide
Also sold as Trulicity. Trulicity helps adults and children 10 years and older manage their type 2 diabetes.
Data updated 2026-05-15
- 85,635
- FDA reportsOften reported
- 1
- InteractionFew interactions
- $471.69
- Brand price (NADAC)
What the data shows
dulaglutide (Trulicity) is a prescription GLP-1 Receptor Agonist, more reported than most tracked drugs (85,635 FDA reports), with 1 documented drug interaction.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
dulaglutide (Trulicity) is a prescription GLP-1 Receptor Agonist. Trulicity helps adults and children 10 years and older manage their type 2 diabetes.
Trulicity is a medicine to help control blood sugar in people with type 2 diabetes. It can also lower the risk of heart problems in adults with both type 2 diabetes and heart disease or heart risk factors.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$471.69/unit
Generic Available
No
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Trulicity helps adults and children 10 years and older manage their type 2 diabetes.
Common side effects
Nausea, Diarrhea, Vomiting
Key warnings
Trulicity may cause thyroid tumors, including a type of thyroid cancer called medullary thyroid carcinoma (MTC).
The sections below are summarized in plain English from dulaglutide's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Trulicity is a GLP-1 receptor agonist. It mimics a natural hormone in your body. This helps your body release insulin when your blood sugar is high and lowers the amount of sugar your liver makes.
Side Effects (from patient reports)
Based on 85,635 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for dulaglutide, by number of reports
- Nausea
Nausea
9,986 reports
- Injection Site Pain
Injection Site Pain
9,796 reports
- Blood Glucose Increased
Blood Glucose Increased
9,762 reports
- Diarrhoea
Diarrhoea
5,737 reports
- Incorrect Dose Administered
Incorrect Dose Administered
5,444 reports
- Vomiting
Vomiting
5,413 reports
- Inappropriate Schedule Of Product Administration 3,806
Inappropriate Schedule Of Product Administration
3,806 reports
- Weight Decreased 3,349
Weight Decreased
3,349 reports
- Decreased Appetite 3,153
Decreased Appetite
3,153 reports
- Injection Site Haemorrhage 3,132
Injection Site Haemorrhage
3,132 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for dulaglutide each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where dulaglutide sits
dulaglutide has more FDA adverse-event reports than 83% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is dulaglutide; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 85,635 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2011–2025.
Total Reports
85,635
Reports Mentioning Death
1,580
1.8% of reports — not proof of cause
Hospitalization Reports
10,007
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | NAUSEA | 9,986 |
| 2 | INJECTION SITE PAIN | 9,796 |
| 3 | BLOOD GLUCOSE INCREASED | 9,762 |
| 4 | DIARRHOEA | 5,737 |
| 5 | INCORRECT DOSE ADMINISTERED | 5,444 |
| 6 | VOMITING | 5,413 |
| 7 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 3,806 |
| 9 | WEIGHT DECREASED | 3,349 |
| 10 | DECREASED APPETITE | 3,153 |
| 11 | INJECTION SITE HAEMORRHAGE | 3,132 |
| 12 | EXTRA DOSE ADMINISTERED | 3,106 |
| 13 | GLYCOSYLATED HAEMOGLOBIN INCREASED | 2,906 |
| 14 | FATIGUE | 2,409 |
| 15 | ACCIDENTAL UNDERDOSE | 2,354 |
| 16 | ABDOMINAL PAIN UPPER | 2,321 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Trulicity may cause thyroid tumors, including a type of thyroid cancer called medullary thyroid carcinoma (MTC). You should not use Trulicity if you or your family have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your doctor if you have a lump in your neck, trouble swallowing, trouble breathing, or a hoarse voice that doesn't go away.
Known Drug Interactions
Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.
Mechanism: Dulaglutide can affect how your body absorbs other pills, which can be risky for drugs like warfarin that need to stay at a very specific level to work safely.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I do if I experience severe stomach pain?
Can Trulicity cause low blood sugar?
What are the symptoms of a serious allergic reaction?
Can Trulicity affect my kidneys?
What if I have severe stomach problems?
Can Trulicity affect my eyes if I have diabetic retinopathy?
What if I think I have gallbladder problems?
Does Trulicity interact with other medications?
How will I know if Trulicity is working?
What if the Trulicity solution looks cloudy or has particles in it?
What are the common side effects of dulaglutide?
Does dulaglutide interact with other medications?
What drug class is dulaglutide?
What pregnancy or breastfeeding source fields are listed for dulaglutide?
Related Medications in GLP-1 Receptor Agonist
Other drugs grouped near dulaglutide - same-class peers and common alternatives.
acarbose
Precose
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes.
Compare with dulaglutide →
alogliptin
Nesina
Compare with dulaglutide →
bromocriptine
Cycloset
Bromocriptine (Cycloset) is a medicine that acts like dopamine in your body.
Compare with dulaglutide →
canagliflozin
Invokana
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Compare with dulaglutide →
colesevelam
Welchol
Colesevelam is a medicine that helps lower bad cholesterol (LDL-C) and control blood sugar in adults.
Compare with dulaglutide →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for dulaglutide: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 85,635.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 1.85%.
- isotretinoin Δ 0.00 pts · 47,513 reports · Systemic Retinoid 1.85%death share
- lifitegrast Δ 0.05 pts · 15,783 reports · LFA-1 Antagonist (Ophthalmic) 1.79%death share
- calcipotriene Δ 0.11 pts · 3,344 reports · Vitamin D Analog (Topical) 1.73%death share
- alirocumab Δ 0.17 pts · 24,428 reports · PCSK9 Inhibitor 2.01%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on dulaglutide
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for dulaglutide
The FDA label for dulaglutide (sold under brand names such as Trulicity) classifies it as a prescription-only medication in the GLP-1 Receptor Agonist class. Trulicity helps adults and children 10 years and older manage their type 2 diabetes. Official labeling lists 5 commonly reported side effects, including Nausea, Diarrhea, Vomiting.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 85,635 voluntary reports. The database also lists 1 documented drug interaction derived from FDA labeling, with the top-flagged interaction rated minor severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: August 5, 2023
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages